Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 12/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6355022 | 0.89 | EPHX2 (0.53) | EPHX2PPARGHDAC3HDAC1HDAC2 | |
| SCHEMBL6361826 | 0.88 | P2RX7 (0.51) | EPHX2HDAC1HDAC6P2RX7 | |
| SCHEMBL6356836 | 0.83 | KDM4E (0.52) | EPHX2PPARGHDAC3HDAC1HDAC2 | |
| SCHEMBL6356880 | 0.82 | HPGD (0.56) | EPHX2PPARGHDAC3HDAC1HDAC2 | |
| SCHEMBL6362493 | 0.81 | P2RX7 (0.49) | EPHX2PPARGHDAC3HDAC1HDAC2 | |
| SCHEMBL5723612 | 0.81 | P2RX7 (0.57) | EPHX2PPARGHDAC3HDAC1HDAC2 | |
| SCHEMBL6357231 | 0.79 | EPHX2 (0.57) | EPHX2PPARGP2RX7ALOX5 | |
| SCHEMBL4576232 | 0.78 | P2RX7 (0.55) | EPHX2PPARGHDAC3HDAC1HDAC2 | |
| SCHEMBL16538118 | 0.78 | P2RX7 (0.57) | EPHX2PPARGHDAC3HDAC1HDAC2 | |
| SCHEMBL507259 | 0.78 | EPHX2 (0.66) | EPHX2PPARGHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | EPHX2 4047/4885PPARG 50/4885HDAC3 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.